Zacks Research Has Bullish Estimate for CPRX Q2 Earnings

Key Points

• Zacks Research raised its Q2 2026 earnings estimate for Catalyst Pharmaceuticals to $0.58 per share, reflecting a slight increase from their previous estimate of $0.57.
• Catalyst Pharmaceuticals received a "strong-buy" rating from Cantor Fitzgerald, contributing to a consensus buy rating among analysts and an average price target of $32.83.
• Insider transactions revealed that two company insiders sold a significant number of shares, amounting to over $1 million, indicating a decrease in their positions within the company.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Equities research analysts at Zacks Research raised their Q2 2026 earnings estimates for shares of Catalyst Pharmaceuticals in a note issued to investors on Tuesday, July 22nd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings of $0.58 per share for the quarter, up from their previous forecast of $0.57. The consensus estimate for Catalyst Pharmaceuticals' current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals' Q3 2026 earnings at $0.64 EPS, Q4 2026 earnings at $0.64 EPS, FY2026 earnings at $2.42 EPS, Q1 2027 earnings at $0.74 EPS, Q2 2027 earnings at $0.62 EPS and FY2027 earnings at $2.60 EPS.

Separately, Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Six research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $32.83.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $21.02 on Friday. The stock has a market cap of $2.56 billion, a P/E ratio of 13.39, a P/E/G ratio of 0.88 and a beta of 0.66. The firm has a 50 day moving average price of $23.03 and a 200 day moving average price of $22.88. Catalyst Pharmaceuticals has a 52-week low of $15.34 and a 52-week high of $26.58.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Preethi Sundaram sold 1,600 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the completion of the transaction, the insider directly owned 41,081 shares of the company's stock, valued at $1,085,360.02. This trade represents a 3.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gary Ingenito sold 44,000 shares of the firm's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the transaction, the insider directly owned 68,873 shares of the company's stock, valued at $1,627,468.99. This represents a 38.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 247,924 shares of company stock worth $5,879,369 over the last 90 days. Corporate insiders own 10.40% of the company's stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several hedge funds have recently made changes to their positions in CPRX. Inspire Investing LLC increased its position in shares of Catalyst Pharmaceuticals by 11.1% during the 2nd quarter. Inspire Investing LLC now owns 37,564 shares of the biopharmaceutical company's stock worth $815,000 after purchasing an additional 3,753 shares during the last quarter. Lokken Investment Group LLC increased its position in shares of Catalyst Pharmaceuticals by 26.6% during the 2nd quarter. Lokken Investment Group LLC now owns 18,098 shares of the biopharmaceutical company's stock worth $393,000 after purchasing an additional 3,799 shares during the last quarter. Maryland State Retirement & Pension System increased its position in shares of Catalyst Pharmaceuticals by 3.0% during the 2nd quarter. Maryland State Retirement & Pension System now owns 33,696 shares of the biopharmaceutical company's stock worth $731,000 after purchasing an additional 990 shares during the last quarter. KLP Kapitalforvaltning AS increased its position in shares of Catalyst Pharmaceuticals by 5.7% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 39,100 shares of the biopharmaceutical company's stock worth $848,000 after purchasing an additional 2,100 shares during the last quarter. Finally, Campbell Newman Asset Management Inc. increased its position in shares of Catalyst Pharmaceuticals by 7.1% during the 2nd quarter. Campbell Newman Asset Management Inc. now owns 93,968 shares of the biopharmaceutical company's stock worth $2,039,000 after purchasing an additional 6,233 shares during the last quarter. 79.22% of the stock is owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.